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Aim: The current study aimed to examine the association between long-term
(36 months) multimodal (pharmacological and psychological) treatment and
psychopathology and health-related quality of life (HRQoL) in children with attention
deficit/hyperactivity disorder (ADHD) from the perspectives of both the children and
parents.
Methods: The sample consisted of 23 children with ADHD (21 boys, 2 girls, mean
age = 13.46 years, SD = 2.36) and 23 healthy control children (11 boys, 12 girls, mean
age = 12.49 years, SD = 1.75). The Mini International Neuropsychiatric Interview for
Children and Adolescents (MINI Kid) was applied to measure psychopathology and
both parent and self-rated versions of the Inventory for the Measure of the Quality
of Life in Children and Adolescents were used to assess HRQoL at baseline and at
the 36-month follow-up visit. The ADHD group took part in multimodal (medical and
behavioral) therapy. The healthy control group did not get any intervention.
Results: At the baseline, the ADHD group was characterized with higher scores in
nine MINI Kid scales and showed lower HRQoL than the control group according to
both children and their parents. At the 36-month follow-up visit six scale scores (ADHD,
social phobia, oppositional defiance and conduct disorder, major depressive episode,
dysthymic disorder) showed statistically significant decreases in the ADHD group, while
these scores were constant in the control group. Parent-rated HRQoL was significantly
lower in the clinical group at baseline than at the end of the study, but there were
no significant changes in the control group. Self-reported changes in HRQoL matched
parent-reported changes.
Interpretation: Multimodal therapy is associated with decreased psychopathology and
improved HRQoL over the long term.
Keywords: ADHD, quality of life, long term, multimodal treatment, comorbid disorders
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INTRODUCTION
Attention deficit hyperactivity disorder (ADHD) is a highly
prevalent behavioral disorder in childhood and adolescence
with early onset (Brown et al., 2001; Polanczyk et al.,
2014) and it may persist into adulthood in 30–60% of
cases (Scahill and Schwab-Stone, 2000). More than 80%
of children with ADHD have at least one comorbid
psychiatric disorder and 50% of them are likely to have
two (Gillberg et al., 2004). Boys with ADHD have more
comorbid externalizing problems and girls with ADHD
(especially adolescents) have more comorbid internalizing
problems such as depression and anxiety (Rucklidge, 2008).
Comorbidity may also play a role in their impairments in social,
emotional, and academic functioning (Loe and Feldman, 2007;
Wehmeier et al., 2010).
Increased family and parental stress appear in the families
of children with ADHD (Theule et al., 2013), which is
likely to be an important factor leading parents to seek
treatment for their child (Cannon et al., 2009). Effective
multimodal treatment exists for the management of ADHD,
including parental education, cognitive behavioral therapy,
and medication (Sonuga-Barke et al., 2013; Hinshaw et al.,
2015; National Institute for Health and Care Excellence,
2018). According to the recommendation of the National
Institute of Clinical Excellence (NICE) clinical guideline
(National Institute for Health and Care Excellence, 2018),
treatment need to be preceded by giving a detailed information
about ADHD which underlies the pharmacological and non-
pharmacological treatment as well. The information should
include the severity of symptoms and impairments, education
on the causes of ADHD, treatment plans, and possible
outcomes. NICE guideline offers for parents and careers a
parent-training program as first-line treatment for children
under 5 years with ADHD or for children aged 5 years
or over who have ADHD and comorbid symptoms of
oppositional defiant disorder or conduct disorder. Parental
training has beneficial effects on parenting and on conduct
problems which commonly co-occur with ADHD (Daley et al.,
2018). According to the NICE guideline (National Institute
for Health and Care Excellence, 2018) methylphenidate is
recommended as the first line pharmacological treatment
for children – aged 5 years or over – with ADHD who
need medication. Cortese et al. (2018) compared ADHD
medications in terms of efficacy on core ADHD symptoms,
clinical global functioning, tolerability, acceptability, and other
clinically important outcomes. Evidence from this meta-analysis
also supports methylphenidate (in children and adolescents)
as the preferred first pharmacological choice for short-term
pharmacological treatment of ADHD.
Quality of life (QoL) can be an important outcome
measure (Coghill, 2010) for understanding the impact
of a mental disorder on patients’ functioning and for
assessing the effectiveness of treatment. There is no clear
separation between the concept of QoL and the concept
of health-related quality of life (HRQoL), the latter being
used in the medical field in many publications (Coghill
et al., 2009). In this paper, the term of HRQoL will be used.
In recent years, HRQoL and its relationship with mental
disorders have become important in child and adolescent
psychiatry (Coghill et al., 2009). HRQoL is a multidimensional
concept that includes the physical, social, and emotional
components of health (Danckaerts et al., 2009). Several
studies have established that children with ADHD have
lower HRQoL than their healthy peers (Danckaerts et al.,
2009; Velõ et al., 2013). It has also been emphasized that
there is low child–parent agreement in rating HRQoL
(Danckaerts et al., 2009; Cortese, 2010; Velõ et al., 2013).
Children with ADHD rate their own HRQoL less negatively
than their parents do, so the assessment of HRQoL from
different perspectives is important. Based on the study of
Dallos et al. (2017) lower self-reported HRQoL of children
with ADHD was associated with female gender and higher
age, furthermore lower HRQoL was related to older age
according to the parents’ report. Having established the
negative effect of ADHD on HRQoL, there is a growing
demand to ascertain the impact of treatment on reducing
ADHD symptoms and improving HRQoL. Coghill et al. (2017)
and Coghill (2010) have systematically reviewed studies of
ADHD medication and HRQoL. These studies revealed a
positive short-term (2–24 weeks) effect for pharmacotherapy
on HRQoL and on the remission of ADHD symptoms.
Flapper and Schoemaker (2008) investigated the impact
of the combined diagnoses of developmental coordination
disorder and ADHD on HRQOL and the effectiveness of
a short-term pharmacological therapy on HRQoL from
the child and proxy perspective. They found significant
improvements in HRQoL reported both by parents and
children after a 4-week period of pharmacological treatment,
in addition to an improvement in the symptoms of ADHD
and motor functioning. Although the short-term effect
for pharmacotherapy on HRQoL and on the remission of
ADHD symptoms are well-described, the persistence of these
effects in long term (>24 weeks) has been understudied.
It is worth mentioning that ADHD is a long-term mental
disease (Biederman et al., 2010), so follow-up studies are
highly important. Coghill (2010) also highlighted the necessity
of a long-term examination and emphasized the urgent
need to measure the impact of psychological therapies on
their own or in combination with medication on HRQoL in
children with ADHD.
Based on all above the current study examines the
association between long-term (36 months) multimodal
(pharmacological and psychological) treatment and
psychopathology (symptoms of both ADHD and
comorbid disorders) as well as HRQoL in children and
adolescents with ADHD from both the children’s and
parents’ perspectives.
Our hypotheses are:
Hypothesis 1. At the end of the study (36 months) children in
the clinical group are characterized with less psychopathology
(both ADHD symptoms and comorbid psychopathology) than
at the baseline.
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Hypothesis 2. At the end of the study (36 months)
children in the clinical group are characterized with better
HRQoL both based on self- and parent’s reports than at
the baseline.
Hypothesis 3. Changes in psychopathology and HRQoL are
independent from gender and social status.
MATERIALS AND METHODS
Participants
We involved into the study a clinical and a healthy control
groups of children. Treatment-naïve children with ADHD
were enrolled in the present study from the Vadaskert
Child Psychiatric Hospital and Outpatient Clinic, Budapest,
Hungary. Definition of treatment-naïve children with
ADHD was: children without previous medication or
psychotherapy treatment of ADHD. We included all
children into the clinical group, whose further combined
treatment was administered according to the instructions
of their child psychiatrist (therapist for their regular
treatment) in the hospital. Addition inclusion criteria
were that children had to meet the diagnostic criteria for
ADHD according to a structured diagnostic interview (see
below) and be between the ages of 6 and 18 years. The
exclusion criterion was mental retardation in the medical
history. Moreover, we excluded in the follow-up study
all children whose child psychiatrist (therapist for their
regular treatment) in the hospital did not suggest further
pharmacological treatment (i.e., lack of efficacy or due
to side effects).
A healthy control population from the same age group
was recruited randomly from elementary schools from
Budapest and the countryside. The exclusion criteria in the
control group were ongoing and/or previous psychological
and/or psychiatric treatment. Lack of any psychiatric
diagnosis was confirmed by a structured psychiatric
interview (see below).
To reveal the role of social background, the groups were
sorted into four categories based on the parents’ educational
and economic status. The Low1 category of children included
those whose parents have completed eight classes or a certificate
of professional qualification or maturity and only one parent
has an active income. In the Low2 category, parents have
the same educational background but both parents have
an active income. Children whose parents have a BA or
an MA degree and only one parent has an active income
are grouped in High1, while children whose parents have
a BA or an MA degree and two active incomes are in
the High2 group.
This study was approved by the Ethical Committee of
the Medical Research Council, Hungary (ETT-TUKEB).
The parents of each child and children older than
14 years of age included in this study provided written
informed consent after being informed of the nature
of the study. No compensation was provided to
the participants.
Measures
Psychiatric Symptoms and Diagnoses
To measure psychopathology and diagnoses both in the clinical
and healthy control groups, the modified version of the
Hungarian Mini International Neuropsychiatric Interview for
Children and Adolescents (MINI Kid) 2.0 (Lecubrier et al., 1997;
Sheehan et al., 1998, 2010; Balázs et al., 2004) was applied. The
MINI Kid is a structured psychiatric interview that assesses 25
DSM-IV child and adolescent psychiatric disorders. Themodified
version of the MINI Kid assesses all of the psychiatric symptoms
of the disorders. The interview is suitable for children aged
between 6 and 18 years; the interview was given to children under
13 years of age in the presence of their parent, while those above
13 years of age received the interview on their own. Based on
the inter-rater reliability, test–retest reliability, sensitivity, and
specificity, the Hungarian version of the MINI Kid proved to
be reliable (Balázs et al., 2004). Before analysis, the scores for
raw symptoms in each section were converted to a 0–100 scale,
with higher scores indicating greater severity of symptoms. In the
present study 13 scales were used: ADHD, oppositional defiant
disorder, conduct disorder, major depressive episode, dysthymic
disorder, (hypo)manic episode, panic disorder, separation anxiety
disorder, social phobia, specific phobia, generalized anxiety
disorder, tic disorder, and obsessive-compulsive disorder.
HRQoL
The Hungarian version of the “Erfassung der Lebensqualität
Kindern und Jugendliche” (Measure of QoL for Children and
Adolescents; ILK) scale (Kiss et al., 2007; Remschmidt and
Mattejat, 2010) was applied to assess HRQoL. The questionnaire
measures general HRQoL in six different domains: school, family,
peer relations, being alone, somatic health, and mental state.
We used both child self-report and a parallel parent-proxy
report format. The child version of the scale used facial
expressions of emotions (laughing, smiling, neutral, sad, and
crying) to evaluate the items. The items were scored on a
5-point Likert scale. Based on the validating study, the Hungarian
version of ILK showed adequate internal consistency (Cronbach’s
alpha ≥0.6), test–retest reliability (Kappa = 0.67–0.75), and
discriminant validity (Kiss et al., 2007). The raw score on
each scale was converted to a 0–100 scale, with higher scores
indicating a better HRQoL.
Procedure
At baseline (T1) following informed consent, the children in
clinical and healthy control groups were evaluated to determine
whether the inclusion criteria were met without any of exclusion
criteria. At first, themodified version of theMINI Kid was applied
to measure psychopathology and diagnoses both groups. In the
case of children under 13 we interviewed the parents and the
children together and according to the manual of the MINI
Kid questions were directed to the children, but the parents
were encouraged to add their opinion and the interviewer made
the final decision, while above 13 we interviewed the children
without their parents. Next, children and parents completed
ILK questionnaires, and parents were asked not to assist their
children during this procedure. After the baseline measurements
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children in the clinical group were medicated with an optimal
dose of methylphenidate, which was administered according to
the instructions of their child psychiatrist (therapist for their
regular treatment). In Hungary both short and long acting
methylphenidate are available. Normally children are suggested
take the morning dose before going to school. Treatment regime
follows the label of methylphenidate. Additionally all children
took part in a 2-week group therapy, named “Fészek” program
(Fészek is the Hungarian word for “Nest”) (Kis et al., 2017)
based on cognitive behavioral therapy at the Vadaskert Child
Psychiatric Hospital. “Fészek” program is a small group for
school-aged children with ADHD. The aims of the 2-week
program are to decrease conduct problems, develop attention
abilities, practice learning strategies, and develop self-esteem
and social competences. Trainers help to apply household rules
and clear limits which are supported by pictures. Household
rules focus on behavioral difficulties of children with ADHD
(e.g., keeping calm when somebody speak, sitting on my
chair, etc.). Trainers also suggest them alternative behaviors
which tent to improve children’s social skills. Children with
ADHD are motivated by praise, encouragement, and rewards for
observing household rules and completing lessons. In the case
of non-desirable behavior, trainers remind children for absence
of reward. Parents of children with ADHD also take part in a
four occasion parent training connecting to “Fészek” program.
The aim of the parent training is to teach parents technics
and strategies which can help them to manage their children’s
difficulties: effective communication and creation of visualized
household rules and techniques to facilitate demand behavior
(i.e., praise, encouragement, rewarding, redirection, distraction,
ignoration, and consequences). Every occasion is interactive and
practical and focuses on everyday life problems of families where
the child/children has/have ADHD.
During the visits, the optimal dose of medication and
behavioral interventions was discussed. Monthly follow-up visits
to assess the multimodal treatment were held in the Outpatient
Department of Vadaskert Hospital, and a detailed general medical
visit was held every 6 months. Control group did not get any
intervention. After 36 months (T2), all children from clinical and
non-clinical groups were contacted again and asked to participate
in a follow-up visit. If a parent did not answer the phone (the
parents gave us their number previously), we contacted them two
further occasions via phone, moreover we sent them regular mail
as well. During the follow-up visit the modified version of the
MINI Kid and the ILK questionnaires was completed again.
Statistical Procedures
Descriptive statistics are reported in the text. The chi-squared
test of independence was calculated to examine the relationship
between categorical variables with the Fisher exact test for 2 × 2
crosstab (group and gender) and Pearson’s chi-square statistics
(group and social status). Phi or Cramer’s V was used as the
measure of associations. An independent sample t-test was
conducted to compare the MINI Kid scales and HRQoL for
the children or parents in the clinical and control group at T1.
Also independent sample t-test was used to compare children
with ADHD who completed the multimodal treatment with
children with ADHD who did not completed the multimodal
treatment regarding age, HRQoL, and ADHD symptoms at
T1. Differences over time between T1 and T2 according to
groups were examined using 2 × 2 mixed analysis of variance
controlling for age (ANCOVA) with Group (clinical vs. control)
as the between-subject factor and Time (T1 vs. T2) as the
within-subject factor to determine the effect of the intervention
on the MINI Kid scales and HRQoL according to children or
parents. Further 2 × 2 × 2 or 2 × 2 × 4 mixed analysis of
variance controlling for age (ANCOVA) was performed for two
between-subject factors (2 × 2: Group and Gender or 2 × 4:
Group and Social status) and Time (T1 vs. T2) to examine the
confounding factors (gender or social status) on the effects of the
intervention on the MINI Kid scales and HRQoL according to
the children or parents. For effect size, partial eta-squares were




The full sample of the ADHD group consisted of 79 children
[64 (81%) boys and 15 (19%) girls] at the baseline stage of the
investigation. Mean age of children with ADHD was 10.24 years
(SD = 2.51, range:10–18). The control group was composed
of 54 children [31 (57.4%) boys and 23 (42.6%) girls] with a
mean age of 9.66 years (SD = 1.73, range: 9–16). There was a
non-significant difference in age between the clinical and the
control group [t(129) = -1.574, p = 0.118]. The gender and the
group revealed a significant relationship [χ2(1) = 8.758, p = 0.006,
8 = 0.26]. The proportions of boys from the clinical group were
81% (64 boys), it was 57.4% (31 boys) in the control group.
The relationship between the social status and the group was
significant [χ2(3) = 25.421, p < 0.001, Cramer’s V = 0.45].
The frequencies of the social status categories differed across
the group levels.
The follow-up sample consisted of 46 children: 23 children in
the clinical group and 23 children in the control group. Table 1
presents the reasons of drop out and the number of participating
children at the 36-month follow-up visit. There was no significant
difference in age [t(44) = -1.576, p = 0.123] between the clinical
(M = 13.46, SD = 2.36) and the control group (M = 12.49,
SD = 1.75).
TABLE 1 | The reasons of drop out and the number of participating children at the





At the baseline visit 79 54
Rejected the participation at the 36-month follow-up visit 27 26
Not available at the 36-month follow-up visit 27 5
Non-medicated during 36 months (excluded) 2 0
At the end of the study (at the 36-month follow-up visit) 23 23
n, number of children.
Frontiers in Psychology | www.frontiersin.org 4 September 2019 | Volume 10 | Article 2037
Velõ et al. Long-Term Treatment of ADHD
The relationship between gender and group was significant
[χ2(1) = 10.268, p = 0.003, 8 = 0.47]. The proportion of
boys from the clinical group was 91.3% (21 boys), whereas the
proportion in the control group was 47.8% 11 boys; Table 1. The
social status of the groups also showed a statistically significant
difference [χ2(3) = 12.468, p = 0.006, Cramer’s V = 0.53].
The frequencies of the High2 and Low2 social statuses differed
across group levels.
There was a non-significant difference in age between the
treatment completers and the non-completers [t(76) = 0.633,
p = 0.530] in the clinical group at T1. The gender and
the group revealed no significant relationship [χ2(1) = 2.234,
p = 0.208, 8 = 0.168]. The proportion of boys from the
completers clinical group was 91.3% (21 boys), while it was
76.8% (43 boys) in the non-completers clinical group at T1.
Social status and the group (completers and non-completers)
revealed no significant relationship [χ2(3) = 5.436, p = 0.143,
8 = 0.266].
MINI Kid Scales and HRQoL in Clinical
and Control Group at T1
There were statistically significant differences between the clinical
and the control groups in 9 of the examined 13 scales of the MINI
Kid at T1, with the exceptions being the scales for panic disorder,
specific phobia, obsessive-compulsive disorder, and tic disorder.
Children in the clinical group were characterized higher scale
scores than the control group (Table 2).
Significant differences appeared between the clinical and
the control group in HRQoL according to both the children
[t(41) = 3.709, p = 0.001] and the parents [t(42) = 8.208,
p < 0.001]. Children in the clinical group showed poorer HRQoL
than the control group. There were no significant difference
in both self- [t(75) = −1.138, p = 0.259] and parent-reported
[t(75) = −0.724, p = 0.471] HRQoL and also in ADHD MINI
Kid scale [t(77) = −0.542, p = 0.591] between completers
(M = 73.32, SD = 18.50) and non-completers (M = 75.65,
SD = 14.10) groups at T1.
Primary Outcomes at T2
MINI Kid Scales
Of the 13 MINI Kid scales, 6 scales showed significant Time
main effect and/or Time × Group interaction. The scores for
these scales indicated statistically significant changes between T1
and T2 independent of Group (clinical vs. control). Scale scores
showed significant decreases independent of Group in Time.
There was also a significant Time × Group interaction in the
scales for major depressive episode and dysthymic disorder, and
the change was different in the groups. The scores for both scales
were constant or increased in a non-significant way in the control
group, whereas these scores decreased significantly in the clinical
group (Figure 1).
For the other four scales – attention deficit/hyperactivity
disorder, social phobia, oppositional defiance, and conduct
disorder – the only significant finding was the Time × Group
interaction effect. The scores for these scales were constant or
increased in a non-significant way in the control group, whereas
they decreased significantly in the clinical group (Figure 1).
There were no significant effects for the remaining seven
scales: (hypo)manic episode, panic disorder, separation anxiety
disorder, specific phobia, obsessive-compulsive disorder, tic
disorder, and generalized anxiety disorder. Based on the means of
the scores of these scales, the scores were constant or increased in
the control group, whereas they decreased in the clinical group in
non-significant way, with the exception of obsessive-compulsive
disorder, the scores for which were constant or followed similar
patterns in both groups, remaining constant in the control group
and increasing non-significantly in the clinical group (Table 3).
HRQoL According to the Children and Parents
Health-related quality of life according to the parents
indicated statistically significant Time × Group interaction
[F(1,41) = 11.264, p = 0.002, η2p = 0.22]. HRQoL was significantly
higher in the clinical group at T2 than at T1, indicating
better HRQoL. In the control group, there were no significant
changes, and based on the means, the HRQoL decreased in
TABLE 2 | MINI Kid scales in the clinical and the control group at T1.
Control Clinical t p
M SD M SD
Major depressive episode 5.53 8.98 34.71 26.56 −4.892 < 0.001
Dysthymic disorder 9.66 14.72 44.44 30.09 −4.891 < 0.001
(Hypo)manic episode 10.51 11.01 45.45 26.82 −5.672 < 0.001
Panic disorder 1.37 3.26 11.00 25.98 −1.726 0.099
Attention deficit/hyperactivity disorder 10.87 14.62 73.32 18.50 −12.701 < 0.001
Separation anxiety disorder 9.06 12.29 26.14 32.96 −2.283 0.031
Social phobia 1.09 5.21 35.23 46.07 −3.455 0.002
Specific phobia 18.48 27.40 20.45 36.71 −0.205 0.838
Obsessive compulsive disorder 1.74 8.34 5.45 15.35 −1.003 0.323
Tic disorder 5.80 15.58 9.42 23.48 −0.617 0.541
Conduct disorder 3.48 4.68 28.34 20.35 −5.586 < 0.001
Oppositional defiance disorder 7.83 9.51 65.00 29.24 −8.740 < 0.001
Generalized anxiety disorder 0.48 2.32 19.05 31.26 −2.715 0.013
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FIGURE 1 | Major depressive episode (A) and dysthymic disorder (B), Attention deficit/hyperactivity disorder (C), social phobia (D), oppositional defiance (E), and
conduct disorder (F) scales in the clinical and the control group at T1 and T2 (error bar: standard error).
non-significant way, indicating an unchanged or worse HRQoL.
HRQoL according the children showed only a marginally
significant Time × Group interaction [F(1,38) = 3.570, p = 0.066,
η
2
p = 0.09]. The changes showed a similar pattern to those in the
parent-reported HRQoL (Figure 2).
Secondary Outcomes at T2
Gender
First, it is important to emphasize that there were only two
girls in the clinical group at T2. There was a statistically
significant Group × Gender interaction for the panic disorder
[F(1,39) = 4.295, p = 0.045, η2p = 0.10] and social phobia
[F(1,40) = 14.023, p = 0.001, η2p = 0.26] scales, which means
that the changes were significantly different in the groups
depending on gender.
The scale for panic disorder was constant or its changes were
non-significant in the control group for both boys and girls. In the
clinical group, it was constant or decreased in a non-significant
way for boys, but increased significantly in girls.
The scale for social phobia was constant or increased in a
non-significant way in the control group for both boys and girls.
In the clinical group, it significantly decreased for both boys and
girls, although this decrease was greater for girls than for boys.
Health-related quality of life according to the children and
parents resulted non-significant main [children: F(1,36) = 0.095,
p= 0.759; parents: F(1,39) = 0.183, p= 0.671] or interaction effects
[children: F(1,36) = 0.300, p = 0.587; parents: F(1,39) = 0.335,
p = 0.566] considering gender.
Social Status
According to both the children and parents, the 13 scales of
the MINI Kid and HRQoL resulted in non-significant main or
interaction effects considering social status.
DISCUSSION
To our knowledge the current study is the first one to
investigate the association between multimodal therapy on
ADHD and comorbid disorders and HRQoL from both the
children’s and parents’ perspectives over the long term. As
mentioned above, several studies have established the positive
short-term effect of pharmacotherapy on HRQoL and on the
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TABLE 3 | MINI Kid scales in the clinical and the control group at T1 and T2.
T1 M (SD) T2 M (SD) Time Time × Group









































































































































1.475 0.231 0.04 2.557 0.117 0.06
SD, standard deviation; F, F-value; p, p-value; η2p, partial eta squared.
FIGURE 2 | HRQoL according to the parents (A) and children (B) in the clinical and the control group at T1 and T2 (error bar: standard error).
remission of ADHD symptoms, but most of these focused
on the acute treatment period, and there is a lack of studies
regarding the impact of multimodal therapies on HRQoL
(Coghill, 2010; Coghill et al., 2017). In addition, the majority of
studies did not allow the recruitment of those with co-morbid
disorders (Coghill, 2010), despite the fact that the existence of
comorbid disorders is more a rule than an exception in ADHD
(Thompson et al., 2004). Our study therefore has major clinical
implications for assessing the possible effects of therapy with
assessment and follow-up on ADHD and comorbid symptoms,
as well as on HRQoL.
At baseline, treatment-naïve children with ADHD showed
higher psychopathology scores and lower levels of HRQoL
than the healthy control group according to both their own
and their parents’ judgment. This result is consistent with
the findings of other investigations that have established
that children with ADHD experience impairment in their
HRQoL (Danckaerts et al., 2009; Velõ et al., 2013). Based
on the conclusions of these studies, effective treatment
of ADHD has to focus not only on the reduction of
symptoms but also on the improvement of patients’ HRQoL
(Coghill, 2010).
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A notable finding of our study is that six symptom scales
showed significant long-term changes over time and these
changes were different between the groups. The symptoms of
ADHD and major depressive disorder, dysthymic disorder,
social phobia, oppositional deviant disorder, and conduct
disorder were decreased in the clinical group, while at the
same time these symptoms were remained constant or
showed a non-significant increase in the control group.
Incidence of major depressive disorder and dysthymic
disorder in the control group appeared to be rising as
these subjects approached adolescence (Costello et al.,
2003; Nobile et al., 2003; Thompson et al., 2004), but our
results showed a decrease over time in the clinical group.
These findings could be due to the multimodal treatment
applied in the clinical group. It may reflect to the floor
effect, that there was no significant change in the control
group; however, the control group could have shown natural
change in time too.
The other important finding was an improvement in
HRQoL in the clinical group from the parents’ perspective,
although there was a slightly negative but non-significant
change in the control group. Based on the evaluation by
the children, there was only a marginally positive change
in HRQoL in the clinical group. We described above, that
previous studies established, lower parent-reported HRQoL
was related to older age (Dallos et al., 2017), and as it
increases over time in the present study, it may suggest
positive interpretation regarding the effectiveness of multimodal
treatment. Further studies on a larger sample are needed to
evaluate which domains of HRQoL are responsible for this
result, as well as the special intervention needs to be based on
these HRQoL domains.
Our findings revealed that changes in ADHD and comorbid
symptoms and HRQoL may be independent of gender and social
status. In the case of two scales (panic disorder and social phobic
disorder) there was a gender effect statistically, but we cannot
draw a conclusion based on these results because only two girls
were in the clinical sample at follow-up.
There are several limitations of the present study which
must be acknowledged. The study focuses only on children
who were able to participate in study for 36 months. Our
result cannot be extended to that population who did not
participate in the multimodal treatment for 36 months. It
can give partly explanation of our second limitation: the low
sample size. During such a long-term program, many children
passed out of the care system, having changed residence, not
requiring further treatment or just did not want to participate
in the extra visit. However, we compared the completers
and non-completers groups in several domains at baseline,
such as age, gender, social status, self- and parent-reported
HRQoL, and symptom severity, and we found no significant
difference between them. The third limitation of the study
we have to add that due to ethical reason we could not
randomized treatment-naïve children with ADHD further into
two groups, i.e., (1) treatment-naïve children with ADHD who
get further treatment for long duration and (2) treatment-naïve
children with ADHD, who do not get further treatment for
long duration. We included all children into the previously
treatment-naïve group, whose further combined treatment
was administered according to the instructions of their child
psychiatrist in the hospital. Fourth, there was a gender difference
between the clinical and control groups, although this does
reflect the experience of clinical practice as well, because
ADHD is more common among boys (Pastor et al., 2011); the
gender ratio was approximately equal in the control sample
as in non-clinical, Hungarian population (Hungary, 2016).
Fifth, although the MINI Kid evaluates a wide range of
child and adolescent DSM-IV psychiatric diagnoses, it is also
important to assess other comorbid disorders, such as learning
disorders that are present in almost 25% of ADHD cases
(Pliszka, 1998). Sixth, we did not assess the physical status
and family structure of the children, which may also have
an impact on HRQoL as well. Seventh, despite the fact that
parents participated in parental training and had half-yearly
consultations with professionals about the effective use of
behavioral interventions, our investigation did not cover whether
parents actually and consistently applied these interventions
with their children. This study result is valid for those children
who could be participated for this study 36 months (i.e., lack
of side effects and having the necessary adherence to the
therapy). Further interpreting our results we should take into
consideration that other factors (i.e., family operation) may lead
to improvements in the HRQoL of children with ADHD not only
multimodal treatment.
Despite these limitations, the current study provides
much valuable information to practitioners. Most of the
studies in this field have demonstrated the short-term
effects of ADHD therapy, while our aim was to evaluate
the possible long-term effects, which is more relevant due
to the persistence of the disease over time (Brown et al.,
2001; Biederman et al., 2010; Polanczyk et al., 2014). The
present study highlights not only the effect of medication,
but also the effect of the combination of medication and
behavioral interventions. In addition to ADHD, we also
give information on the comorbid disorders, which can
play a significant role in the patient’s HRQoL. Finally,
our study measures the disorders using a dimensional
approach, which adds more information about the possible
effects of the therapy.
CONCLUSION
In conclusion, our study highlights that multimodal therapy
has beneficial long-term effects not only in the decrease of
ADHD symptoms, but also in the relief of the comorbid
disorders. These positive effects are also reflected in the changes
in the HRQoL of patients, which was perceived by both the
parents and children. Although the questionnaire methods
provide reliable information about HRQoL, the experienced
changes as a result of treatment cannot be precisely identified
from the children’s perspective. In assessing the HRQoL,
for further research should therefore consider the use of
qualitative interviews, with could provide much more detailed
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information about the effects of therapy on the HRQoL of
children with ADHD.
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